Access begins with Artia.
Artia Solutions launched over 32% of all drugs approved in the U.S. in 2023.
From drug launch strategy to supplemental rebate bid analysis to product access monitoring, we set the standard in Medicaid consulting.
Our Story
After several years in the pharmaceutical industry—and two years as the pharmacy director of Florida Medicaid—George Kitchens, RPh, saw a need for strategic Medicaid access consulting for drug manufacturers. The light bulb went off, and he founded Artia Solutions in 2005. The one-man show quickly grew into a full-fledged national Medicaid consulting firm with over 30 employees. Artia’s team of PharmDs and analysts holds more than 100 years of combined Medicaid policy, administrative, clinical, legislative, and budgeting experience.
Supporting Solutions
Our custom-built technology and curated tools assist our clients in effectively forecasting access upon launch, understanding coverage landscapes, and monitoring their products post-launch.
More on our productsThe App
The Artia App, available for iOS and Android, provides Medicaid P&T and DUR meeting information and market share data for every state.
Learn MoreThe Atlas
The Atlas is our comprehensive, industry-leading online portal containing all necessary components for Medicaid drug coverage monitoring.
Learn MoreFeatured Clients
Our clients range from new drug manufacturers with a specialty drug to drug manufacturers with an established portfolio. Regardless of company size or service level, we're dedicated to the hard work that a successful Medicaid access strategy requires. It’s a journey, and we’re with our clients every step of the way to ensure the most favorable outcome.
New From Our Blog
More
Reimbursement Challenges with High-Cost Inpatient Drugs
The management and reimbursement of inpatient drug costs in Medicaid programs are pivotal topics, especially with the proliferation of high-cost therapies. The emergence of expensive inpatient drugs, such as cell and gene therapies, have challenged Diagnosis Related Groups (DRGs), the traditional bundled payment system used by hospitals.
Read MoreCell and Gene Therapy Access Model from CMS Offers New Perspective to Value-Based Purchasing Agreements
Will the involvement of a federal agency change the progress of value-based purchasing in the Medicaid program? The 2024 calendar year will provide insight into whether this intervention will expand opportunities for states and manufacturers.
Read MoreFlorida Senate Passes Resolution Recognizing February 15, 2024, as Angelman Syndrome Awareness Day
Artia Solutions and The Garner Group are proud to support the recognition of February 15, 2024, as Angelman Syndrome Awareness Day in the state of Florida through SR 1802, sponsored by Senator Alexis Calatayud, R-Miami Dade.
Read More